Major R&D Pipeline: 3ADCs
Major R&D Milestones in FY2021 (Alpha)
FY2021
Project
Target Indications [phase, study name, region]
Q1
Q2
Quizartinib
AML, 1L [P3, JP/US/EU/Asia]
Pexidartinib
Tenosynovial giant cell tumor [P2, JP]
Teserpaturev/G47A Malignant glioma [IIS, JP]
Study started
Approved
ATL/lymphoma [P2 registration, JP]
DS-3201
PTCL [P2 registration, JP/US/EU/Asia]
AML, ALL [P1/2, US]
As of July 2021
Q3
Q4
TLR anticipated
TLR obtained
Submission anticipated (Japan)
Study started
Study started
Approval anticipated
Approval anticipated
DS-1594
R
Lixiana
R
Efient
Tarlige®
AF in the very elderly [P3, ELDERCARE-AF, JP]
Ischemic stroke [P3, PRASTRO III, JP]
Central neuropathic pain [P3, JP]
Submitted
DS-6016
Fibrodysplasia Ossificans Progressiva [P1, JP]
Study started
VN-0200
RS virus vaccine [P1, JP]
Study started
Red underlined: new or updated from FY2020 Q4
AF: atrial fibrillation, ALL: acute lymphoblastic leukemia, AML: acute myeloid leukemia, ATL: adult T-cell leukemia, IIS: investigator-initiated study, PTCL: peripheral T-cell lymphoma,
TLR: Top Line Results
Daiichi-Sankyo
34View entire presentation